Pipeline development and regulatory risk
Drug candidates must clear preclinical, IND, and clinical hurdles before commercialization.
- Scope
- SPC-15, SP-26, SPC-14, SPU-16
- Materiality
- high
Silo Pharma, Inc.
Silo Pharma, Inc. is a U.S.-based developmental-stage biopharmaceutical company focused on licensing, developing, and advancing drug candidates for central nervous system and stress-related disorders. Its pipeline includes intranasal, implantable, and peptide-based programs, and the company also holds digital assets as part of a treasury strategy.
38,6 %
−5 863,5 %
11.36
11.36
| % | |
|---|---|
| Lead therapeutic programs | 70% Development-stage drug candidates targeting PTSD, anxiety, fibromyalgia, and CNS disorders. |
| Drug delivery technology | 15% Intranasal and other delivery mechanisms used to improve targeting and onset of action. |
| Licensed intellectual property | 10% Exclusive and option-based rights to external inventions and patents supporting the pipeline. |
| Digital asset treasury | 5% Cryptocurrency holdings and related treasury activities outside the core therapeutics business. |
Silo Pharma does not sell commercial medicines at scale; its economic counterparties are primarily licensors, research...
- IP licensors and research institutionsprimary
Provide patents, compounds, or delivery technologies that Silo licenses to build its pipeline.
- Clinical development partnersprimary
Support preclinical, toxicology, and regulatory-enabling studies for candidate advancement.
- Future specialty-care patientsemerging
Patients with PTSD, stress-induced anxiety, fibromyalgia, Alzheimer’s disease, or neuroinflammatory conditions who would use approved products.
- Healthcare providersemerging
Psychiatrists, neurologists, pain specialists, and other clinicians who would prescribe or administer therapies.
Silo Pharma is headquartered in the United States and conducts its business through U.S...
- •Headquartered in the United States
- •Regulatory interactions are centered on the U.S. FDA
- •Licensing and research rights may be worldwide for some programs
- •Development work is driven by U.S.-based corporate operations
- •No country-level revenue disclosure was provided in the excerpts
Silo Pharma’s strategy is to license or acquire external intellectual property, fund development, and advance a small...
01
Advance SPC-15 through regulatory developmentshort-term
SPC-15 is the lead program and the clearest path to a clinical-stage asset.
02
Build a broader CNS and pain pipelinemedium-term
Multiple programs reduce dependence on a single asset and expand optionality.
03
License external IP and technology rightsmedium-term
The company relies on external inventions to source differentiated candidates.
04
Develop digital asset treasury capabilitiesshort-term
The treasury strategy creates a separate investment framework and capital use case.
Silo Pharma faces the typical risks of a development-stage biotech company: clinical, regulatory, and intellectual...
Intellectual property and licensing dependence
The business depends on rights from third parties and may face renewal, scope, or royalty constraints.
- Scope
- Medspray license, UMB option, university-originated assets
- Materiality
- high
Cryptocurrency market and treasury execution risk
Digital assets can be volatile and operational mistakes in custody or trading can create losses.
- Scope
- Bitcoin, Ethereum, Solana, digital asset holdings
- Materiality
- high
Nasdaq listing and financing risk
Maintaining exchange listing supports liquidity and access to capital for a pre-revenue biotech.
- Scope
- Common stock market access
- Materiality
- medium
Competition in CNS and psychedelic medicine
Other developers are pursuing similar indications, delivery methods, and assets.
- Scope
- PTSD, anxiety, fibromyalgia, Alzheimer’s, neuroinflammatory disease
- Materiality
- medium
Research and development expense recognition
Can create volatility in quarterly operating results
Stock-based compensation
Affects operating expenses and diluted share count
License revenue recognition
Produces small, deferred revenue recognition rather than upfront sales
Digital asset accounting
Can materially affect other income and balance sheet values
Solana Co
HSDT · Finance Services
Solana Co is a U.S.-based public company organized around a Solana digital asset treasury strategy, with Solana (SOL) as its primary treasury reserve asset.
Silexion Therapeutics Corp
SLXN · Biological Products, (No Diagnostic Substances)
Silexion Therapeutics Corp is a U.S.-listed holding company whose operations are conducted primarily through its subsidiary Silexion, a clinical-stage…
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
Kairos Pharma, LTD.
KAPA · Pharmaceutical Preparations
Serina Therapeutics, Inc.
SER · Pharmaceutical Preparations
CERO THERAPEUTICS HOLDINGS, INC.
CERO · Biological Products, (No Diagnostic Substances)
: 29/04/2026